As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
7 Analysts have issued a Genprex, Inc. forecast:
7 Analysts have issued a Genprex, Inc. forecast:
| Dec '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -21 -21 |
32%
32%
|
|
| EBIT (Operating Income) EBIT | -21 -21 |
32%
32%
|
|
| Net Profit | -21 -21 |
31%
31%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.
| Head office | United States |
| CEO | Ryan Confer |
| Employees | 15 |
| Founded | 2009 |
| Website | www.genprex.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


